BIO Asia–Taiwan 2022 亞洲生技大會

BIO Asia–Taiwan 2022 亞洲生技大會

TEACHER

Tsai-Kun Li

Session 5 – New Modalities to Cure

Date:27 July (Wednesday)
Time:  15:40 – 17:10 (GMT+8)

Tsai-Kun Li

Vice President, for R & D
Development Center for Biotechnology

​​

Education
▌Ph.D. in Pharmacology from the Rutgers University and University of Medicine and Dentistry of New Jersey, U.S.A.
 
Experience
▌Professor, Dept. & Graduate Institute of Microbiology, National Taiwan University
▌Deputy Vice President, Academic Affairs, National Taiwan University
▌CEO, NTU Centers for Genome and Precision Medicine, National Taiwan University
▌Distinguished Expert, Development Center for Biotechnology
▌Advisory Committee Member, National Sun Yat-sen University
▌Dean, International College Provisional Office, National Taiwan University
▌Associate Dean, College of Medicine, National Taiwan University
▌Director, Office for International Affairs, College of Medicine, National Taiwan University
▌Board Member, VSENCE Co., Ltd.
▌Professor, School of Integrative and Global Majors, University of Tsukuba

 

Speech title & Synopsis

Development of nucleic acid medicine in relation with CDMO

The content will include a basic introduction of the development of new modalities (including PROTAC, ADC and nucleic acid medicine) at DCB, and then following up mainly with the development of nucleic acid medicine (including short- and long-chain nucleic acid medicine, such as antisense oligonucleotides and mRNA medicine) as well as lipid nanoparticles (LNPs) and new conformation RNA (e.g. saRNA and oRNA). The talk will be ended with aspects of CDMO industry for nucleic acid medicine.